SCOPE Summit 2021

SCOPE Summit 2021

March 2-4, 2021

Join pharmaceutical and biotech experts to discuss the latest trends and opportunities in the industry at SCOPE Summit, March 2-4 2021. 

ERT’s Matt McCarty, Vice President, Integrated Customer Solutions, will present ‘The New Patient Budern’ on March 4, 2021 at 12:30 pm ET. This presentation will focus on problems and solutions created by virtual trials and how technology can support successful patient submission of high-quality data. 

Matt Johnson, VP of Wearables and Digital Biomarkers at ERT will be a leader in a virtual panel discussion, ‘From Digital Endpoints to Digital Trials to Digital Healthcare and Back’ on March 2, 2021 at 4:05 pm ET. This session will discuss the latest advancements in wearables and digital biomarkers in clinical trials.

Make sure to stop by our virtual booth and speak with ERT experts who will be available to answer any of your questions about how to implement virtual solutions in your next clinical trial. 

Join us there!


Matt Johnson

VP, Wearables & Digital Biomarkers

Matthew Johnson is a digital health entrepreneur driven to improve healthcare delivery through advances in technology. Serving as the General Manager & Chief Commercial Officer, Matthew’s first company, APDM Wearable Technologies, was acquired by ERT on June 9, 2020 and became ERT’s Wearables & Digital Biomarkers product line. ERT is a global data and technology company serving Pharma, Biotechs, and CROs, who have relied on ERT solutions in over 13,000 studies spanning more than three million patients to date. His current strategic interest is improving clinical trials by developing and introducing the next generation of scientifically validated digital endpoints. Matt’s next strategic initiative will be coupling these digital technologies and endpoints to therapeutics to enable precision medicine on a global scale.

Matt McCarty

VP, Integrated Customer Solutions

Matt is responsible for defining and leading the strategy for ERT’s integrated product offering with a specific focus on patient and site experience and decentralisation. Matt has spent the last 12 years leading teams and innovating products in both the clinical research and commercial healthcare settings to reduce the patient burden of participation and to support patients in their healthcare journey. Most recently, Matt was Global Head of Patient Engagement for ICON’s Commercialization & Outcomes division and, prior to that, Head of Direct to Patient Research (Virtual Trials) at IQVIA.